Skip to main content

Rivfloza FDA Approval History

Last updated by Judith Stewart, BPharm on May 13, 2025.

FDA Approved: Yes (First approved September 29, 2023)
Brand name: Rivfloza
Generic name: nedosiran
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Primary Hyperoxaluria

Rivfloza (nedosiran) is a lactate dehydrogenase A (LDHA) directed small interfering RNA used to lower urinary oxalate levels in patients with primary hyperoxaluria type 1.

Development timeline for Rivfloza

DateArticle
Oct  2, 2023Approval FDA Approves Rivfloza (nedosiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.